{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:37:43Z","timestamp":1792643863505,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A novel therapeutic strategy to decrease the development of femoral head deformity after ischemic osteonecrosis was studied in a large animal model of total head infarction. RANKL inhibition through exogenous osteoprotegerin administration significantly decreased pathologic bone resorption and deformity during repair of the infarcted head.<\/jats:p>\n               <jats:p>Introduction: Legg-Calv\u00e9-Perthes disease (LCPD) is a juvenile form of osteonecrosis of the femoral head that can produce permanent femoral head deformity (FHD) and premature osteoarthritis. The development of FHD in LCPD is closely associated with the repair process, characterized by a predominance of bone resorption in its early stage that produces a fragmented appearance and collapse of the femoral head. We present here a novel strategy to preserve the femoral head structure after ischemic osteonecrosis based on inhibition of interaction between RANK and RANKL using exogenous administration of osteoprotegerin (OPG-Fc) in a large animal model of ischemic osteonecrosis.<\/jats:p>\n               <jats:p>Materials and Methods: Ischemic osteonecrosis was surgically induced in 18 male piglets by placing a ligature tightly around the right femoral neck to disrupt the blood flow to the right femoral head. Two weeks after the induction of total head infarction, OPG-Fc or saline was administered subcutaneously to nine animals per group for 6 weeks. The contralateral, normal (left) femoral heads from the animals treated with saline served as normal, nondisease controls. All animals were killed at 8 weeks when severe FHD has been previously shown to occur because of the repair process dominated by osteoclastic bone resorption. Radiographic, histomorphometric, and immunohistochemical assessments were performed.<\/jats:p>\n               <jats:p>Results: Radiographic assessment showed significantly better preservation of the femoral head structure in the OPG-Fc group compared with the saline group. Epiphyseal quotient (the ratio of epiphyseal height to diameter) was significantly higher in the OPG-Fc group (0.41 \u00b1 0.09) compared with the saline group (0.24 \u00b1 0.08, p &amp;lt; 0.001). Histomorphometric assessment revealed a significant reduction in the number of osteoclasts present in the OPG-Fc group (5.9 \u00b1 5.3mm\u22122) compared with the saline group (39.6 \u00b1 13.8 mm\u22122, p &amp;lt; 0.001). Trabecular bone volume, number, and separation were significantly better preserved in the OPG-Fc group compared with the saline group (p &amp;lt; 0.001). No significant difference in femoral length was observed between the OPG-Fc and saline groups. Immunostaining revealed the presence of OPG-Fc only within the blood vessels, with no apparent staining of bone matrix or trabecular bone surfaces.<\/jats:p>\n               <jats:p>Conclusions: To our knowledge, this is the first study to show that RANKL inhibition decreases bone resorption and FHD after ischemic osteonecrosis. Because RANKL inhibitors do not bind to bone, their effects on resorption are reversible as the drug is cleared from circulation. The reversible nature of RANKL inhibitors is very appealing for treating pediatric bone diseases such as LCPD, where the resorptive stage of the disease lasts for 1\u20132 years.<\/jats:p>","DOI":"10.1359\/jbmr.060905","type":"journal-article","created":{"date-parts":[[2006,9,29]],"date-time":"2006-09-29T14:58:12Z","timestamp":1159541892000},"page":"1946-1954","source":"Crossref","is-referenced-by-count":72,"title":["RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis"],"prefix":"10.1093","volume":"21","author":[{"given":"Harry KW","family":"Kim","sequence":"first","affiliation":[{"name":"Center for Research in Skeletal Development and Pediatric Orthopaedics, Shriners Hospitals for Children, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Morgan-Bagley","sequence":"additional","affiliation":[{"name":"Center for Research in Skeletal Development and Pediatric Orthopaedics, Shriners Hospitals for Children, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kostenuik","sequence":"additional","affiliation":[{"name":"Metabolic Disorders Research, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019372586900_bib1","first-page":"119","volume-title":"Instructional Course Lectures","author":"Aronson","year":"1986"},{"key":"2024013019372586900_bib2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2106\/00004623-198466060-00006","article-title":"A long-tern follow-up of Legg-Calve-Perthes disease","volume":"66","author":"Mc Andrew","year":"1984","journal-title":"J Bone Joint Surg Am"},{"key":"2024013019372586900_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1302\/0301-620X.64B3.6807991","article-title":"A review of the morphology of Perthes' disease","volume":"64","author":"Catterall","year":"1982","journal-title":"J Bone Joint Surg Br"},{"key":"2024013019372586900_bib4","first-page":"25","article-title":"Coxa plana. A histo-pathologic and arthographic study","volume":"12","author":"Jonsater","year":"1953","journal-title":"Acta Orthop Scand Suppl"},{"key":"2024013019372586900_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1302\/0301-620X.58B3.956251","article-title":"Legg-Calve-Perthes' disease\u2014 morphological studies in two cases examined at necropsy","volume":"58","author":"Jensen","year":"1976","journal-title":"J Bone Joint Surg Br"},{"key":"2024013019372586900_bib6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1302\/0301-620X.56B3.438","article-title":"Pathological changes in a case of Perthes' disease","volume":"56","author":"McKibbin","year":"1974","journal-title":"J Bone Joint Surg Br"},{"key":"2024013019372586900_bib7","first-page":"951","volume-title":"Lovell and Winter's Pediatric Orthopaedics","author":"Weinstein","year":"1996","edition":"4th ed."},{"key":"2024013019372586900_bib8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2106\/00004623-200208000-00007","article-title":"Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model","volume":"84","author":"Kim","year":"2002","journal-title":"J Bone Joint Surg Am"},{"key":"2024013019372586900_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2474-3-19","article-title":"Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats","volume":"3","author":"Astrand","year":"2002","journal-title":"BMC Musculoskelet Disord"},{"key":"2024013019372586900_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2106\/00004623-200503000-00011","article-title":"Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs","volume":"87","author":"Kim","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"2024013019372586900_bib11","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1359\/jbmr.2003.18.11.2016","article-title":"Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats","volume":"18","author":"Little","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019372586900_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.orthres.2004.11.015","article-title":"Zoledronic acid improves femoral head sphericity in a rat model of perthes disease","volume":"23","author":"Little","year":"2005","journal-title":"J Orthop Res"},{"key":"2024013019372586900_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/keh481","article-title":"Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study","volume":"44","author":"Agarwala","year":"2005","journal-title":"Rheumatol"},{"key":"2024013019372586900_bib14","first-page":"2155","article-title":"The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study","volume":"87","author":"Lai","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"2024013019372586900_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"2024013019372586900_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: Involvement in the orchestration of pathophysiological bone remodeling","volume":"15","author":"Theoleyre","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"2024013019372586900_bib17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1381612013397807","article-title":"Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption","volume":"7","author":"Kostenuik","year":"2001","journal-title":"Curr Pharm Des"},{"key":"2024013019372586900_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"2024013019372586900_bib19","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024013019372586900_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"2024013019372586900_bib21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2106\/00004623-200105000-00007","article-title":"Histopathologic changes in growth plate cartilage following ischemic necrosis of the capital femoral epiphysis","volume":"83","author":"Kim","year":"2001","journal-title":"J Bone Joint Surg Am"},{"key":"2024013019372586900_bib22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019372586900_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0736-0266(03)00135-9","article-title":"Indentation properties of growing femoral head following ischemic necrosis","volume":"22","author":"Pringle","year":"2004","journal-title":"J Orthop Res"},{"key":"2024013019372586900_bib24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2106\/00004623-195032040-00004","article-title":"Legg-Perthes disease: A method for the measurement of the roentgenographic result","volume":"32","author":"Heyman","year":"1950","journal-title":"J Bone Joint Surg Am"},{"key":"2024013019372586900_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1439-0442.2001.00392.x","article-title":"Comparison of blood markers for the longitudinal monitoring of osteoclastic activity in the pig","volume":"48","author":"Weile","year":"2001","journal-title":"J Vet Med A Physiol Pathol Clin Med"},{"key":"2024013019372586900_bib26","volume-title":"Bone Histomorphometry","author":"Eriksen","year":"1994"},{"key":"2024013019372586900_bib27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024013019372586900_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1359\/jbmr.2002.17.2.192","article-title":"In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis","volume":"17","author":"Childs","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019372586900_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"Min","year":"2000","journal-title":"J Exp Med"},{"key":"2024013019372586900_bib30","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","article-title":"The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy","volume":"146","author":"Morony","year":"2005","journal-title":"Endocrinology"},{"key":"2024013019372586900_bib31","first-page":"2572","article-title":"Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy","volume":"61","author":"Oyajobi","year":"2001","journal-title":"Cancer Res"},{"key":"2024013019372586900_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0002-9440(10)63144-6","article-title":"Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis","volume":"164","author":"Redlich","year":"2004","journal-title":"Am J Pathol"},{"key":"2024013019372586900_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00003086-198007000-00019","article-title":"Methods of measuring in Legg-Calve-Perthes Disease with special regard to the prognosis","volume":"150","author":"Mose","year":"1980","journal-title":"Clin Orthop"},{"key":"2024013019372586900_bib34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2106\/00004623-198163070-00006","article-title":"The natural history of Legg-Calve-Perthes disease","volume":"63","author":"Stulberg","year":"1981","journal-title":"J Bone Joint Surg Am"},{"key":"2024013019372586900_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01202412-199907000-00005","article-title":"Long-term prognosis of Legg-Calve-Perthes disease: A meta-analysis","volume":"8","author":"Yrjonen","year":"1999","journal-title":"J Pediatr Orthop B"},{"key":"2024013019372586900_bib36","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res"},{"key":"2024013019372586900_bib37","first-page":"276","article-title":"RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis","volume":"4","author":"Ritchlin","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2024013019372586900_bib38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","article-title":"Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis","volume":"161","author":"Romas","year":"2002","journal-title":"Am J Pathol"},{"key":"2024013019372586900_bib39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo","volume":"255","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"2024013019372586900_bib40","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology"},{"key":"2024013019372586900_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2005.03.013","article-title":"Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats","volume":"37","author":"Valenta","year":"2005","journal-title":"Bone"},{"key":"2024013019372586900_bib42","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.21021","article-title":"Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models","volume":"52","author":"Schett","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024013019372586900_bib43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: Mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"2024013019372586900_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bone.2005.12.019","article-title":"Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head","volume":"39","author":"Kim","year":"2006","journal-title":"Bone"},{"key":"2024013019372586900_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"2024013019372586900_bib46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pharmtox.38.1.375","article-title":"Mechanisms of action of bisphosphonates","volume":"38","author":"Rodan","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2024013019372586900_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/8756-3282(95)00439-4","article-title":"Long-term effects of clodronate on growing rat bone","volume":"18","author":"Lepola","year":"1996","journal-title":"Bone"},{"key":"2024013019372586900_bib48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/jbmr.2001.16.3.429","article-title":"Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats","volume":"16","author":"Li","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019372586900_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"2024013019372586900_bib50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.060905","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/12\/1946\/56478526\/5650211216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/12\/1946\/56478526\/5650211216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:47:44Z","timestamp":1710341264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/12\/1946-1954\/7593179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,1]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,12,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.060905","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,12,1]]},"published":{"date-parts":[[2006,12,1]]}}}